Neuropace Inc SEC Filings

NeuroPace, Inc. (NPCE) reported Q3 2025 results with revenue of $27,354,000 versus $21,060,000 a year ago, reflecting strong year-over-year growth. Gross profit was $21,168,000, and the company recorded a net loss of $3,496,000 compared to a $5,452,000 loss in Q3 2024. Year-to-date, revenue reached $73,398,000 with a net loss of $18,736,000.

As of September 30, 2025, cash, cash equivalents and short-term investments totaled $60,000,000. Long-term debt was $58,748,000 after the June refinancing that repaid the CRG term loan and established a new MidCap term loan maturing in 2030. The company completed a February follow-on offering of 7,475,000 shares at $10.00 per share for net proceeds of $69,700,000 and used $49,500,000 to repurchase 5,270,845 shares from a significant stockholder at $9.40 per share.

Management states compliance with MidCap liquidity and revenue covenants, with trailing 12‑month RNS System net revenue of $77,000,000 as of September 30, 2025. The DIXI Medical U.S. distribution agreement expired on September 30, 2025 and is in a six‑month wind‑down period.

NeuroPace, Inc. (NPCE) reported it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release, dated November 4, 2025, is furnished as Exhibit 99.1.

The company clarified the information is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings unless specifically referenced.

NeuroPace insider shares issued to director as compensation. Director Uri Geiger was issued 1,194 shares of NeuroPace common stock on 09/19/2025 at a reported per-share value of $9.94 under the company's non-employee director compensation policy in lieu of a quarterly cash retainer. After the issuance, Mr. Geiger directly beneficially owns 13,230 shares. He also reports indirect beneficial ownership of 4,432,948 shares held by Accelmed Partners II LP, for which he states sole voting and dispositive power via his role as managing partner of the general partner entities.

NeuroPace Inc. (NPCE) Form 4: Director Joseph Lacob was issued 1,131 shares of NeuroPace common stock on 09/19/2025 at a price of $9.94 per share under the company's non-employee director compensation policy in lieu of quarterly retainer fees. After the issuance, Mr. Lacob directly beneficially owns 13,211 shares and holds additional indirect holdings of 128,174 shares through Lacob Ventures LLC and 223,554 shares through LCT18 Investments, as disclosed on the Form 4. The filing was signed by an attorney-in-fact on 09/22/2025.

NeuroPace director Kumar Rakhi received 1,509 shares of common stock as compensation on 09/19/2025 at a price of $9.94 per share. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly retainer fees, increasing the reporting person’s total beneficial ownership to 17,103 shares following the transaction.

The Form 4 reports this as a non-derivative acquisition and was filed as a single-person report. The disclosure identifies the transaction code as an issuance for compensation and states the reporting person’s relationship to the issuer as a director.

NeuroPace director Frank M. Fischer acquired 2,389 shares of NeuroPace common stock on 09/19/2025 at a price of $9.94 per share. The Form 4 reports that these shares were issued to Mr. Fischer pursuant to the issuer's non-employee director compensation policy in lieu of quarterly retainer fees. After the reported transaction, the filing shows Mr. Fischer beneficially owns 591,920 shares. The Form 4 is a single-reporting-person filing and lists the reporting person as a company director.

NeuroPace insider filing: Martha Morrell, listed as Chief Medical Officer and a director-level reporting person, reported a non-sale disposition on 09/03/2025. The form shows 1,337 shares of NeuroPace common stock were withheld by the issuer at a reported price of $9.36 to satisfy tax withholding related to the vesting of a restricted stock unit award. After that withholding, Morrell beneficially owns 83,480 shares as reported. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and was filed as a single-person report.

KCK Ltd., a Bermuda entity, filed an amendment on Schedule 13G reporting zero beneficial ownership of NeuroPace Inc common stock (CUSIP 641288105). The filing indicates KCK Ltd. holds no sole or shared voting or dispositive power and represents 0.0% of the class. The document checks the appropriate rule designation and states that items related to group ownership, parent holding company identification and ownership on behalf of another person are not applicable. The filing is signed by KCK Ltd.'s secretary, certifying the accuracy of the statement.

Joel Becker, Chief Executive Officer and director of NeuroPace Inc. (NPCE), reported a non-discretionary share disposal on 08/27/2025. The filing shows 1,126 shares were withheld by the issuer at an effective price of $8.88 to satisfy tax withholding tied to the vesting of a restricted stock unit award. After this withholding, Becker beneficially owns 104,212 shares, held directly. The form was signed by an attorney-in-fact on 08/28/2025 and records the transaction as a routine tax-withholding disposition related to equity compensation.